Last reviewed · How we verify
ABBV-706
ABBV-706 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage proliferation and activation in the tumor microenvironment.
ABBV-706 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage proliferation and activation in the tumor microenvironment. Used for Advanced solid tumors (in combination with checkpoint inhibitors), Non-small cell lung cancer.
At a glance
| Generic name | ABBV-706 |
|---|---|
| Sponsor | AbbVie |
| Drug class | CSF1R inhibitor |
| Target | CSF1R (Colony-Stimulating Factor 1 Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CSF1R inhibition depletes tumor-associated macrophages (TAMs) and suppresses their pro-tumoral functions, including immunosuppression and angiogenesis support. By reducing macrophage-mediated immune evasion, ABBV-706 aims to enhance anti-tumor immunity and improve efficacy when combined with checkpoint inhibitors or other immunotherapies.
Approved indications
- Advanced solid tumors (in combination with checkpoint inhibitors)
- Non-small cell lung cancer
Common side effects
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- Expanded Access to ABBV-706
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer (PHASE3)
- Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-706 CI brief — competitive landscape report
- ABBV-706 updates RSS · CI watch RSS
- AbbVie portfolio CI